LONDON, April 23, 2013 /PRNewswire/ --
Following the expiration of patents on several blockbuster drugs, big pharma companies have been looking to boost their product pipeline. While in-house research and development will be crucial to boost product pipeline, major pharma companies may also benefit by collaborating with emerging biotechnology companies that have developed or are developing potential blockbuster drugs. Biotechnology stocks ended mostly lower on Monday even as the broad market rose for a second successive trading session. Among the major movers in the biotechnology sector yesterday were MannKind Corporation (NASDAQ: MNKD), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Galena Biopharma Inc. (NASDAQ: GALE), and Novavax Inc. (NASDAQ: NVAX). StockCall has released full comprehensive research on MNKD, ARIA, ZIOP, GALE, and NVAX and these free technical analyses can be downloaded by signing up at
Shares of MannKind Corporation edged lower on Monday. The stock traded between $3.86 and $4.07 before finishing the day 0.50% lower at $3.99 on volume of 2.70 million. MannKind's shares are currently trading more than 11.30% below their 52-week high. The stock has had an excellent run so far in 2013, gaining more than 72.70%. Shares of MNKD are currently trading well above their 50-day and 200-day moving averages which is a bullish signal. Free technical analysis on MNKD available by signing up at
Copyright©2012 PR Newswire.
All rights reserved